Please provide your email address to receive an email when new articles are posted on . Patients with breast cancer who developed tamoxifen-associated uterine cancer had fewer phosphatidylinositol ...
Myriad of Groups Are Working on the Latest Hot Target and Most Are Optimistic About Its Potential Although the term “signal transduction” was coined back in 1972, cell-signaling switches have only ...
Variation in health-related quality of life (HRQOL) by line of therapy, age, and gender among patients with chronic lymphocytic leukemia. Predictive factors associated with achievement of major ...
TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. This is an ASCO Meeting Abstract from the 2014 ASCO Annual ...
SAN FRANCISCO – While some targeted therapies – drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells – work well by themselves, increasingly ...
The EGFR cell-signaling pathway plays a central role in processes such as cell growth, proliferation, survival, and differentiation. Understanding the biological role of this pathway and its effect in ...
CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...
In a recent study under review at the journal Molecular Medicine and currently available on the Research Square* preprint server, researchers in China investigate the role of phosphatidylinositol 3 ...
A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback